A majority of U.S. physicians disagree with the decision by the Food and Drug Administration to approve the Alzheimer’s drug from Biogen (BIIB) and believe the medicine should not be routinely used for patients, according to a new survey from STAT and Medscape.
In addition, nearly two-thirds of the 200 primary care physicians and neurologists polled said they find the trial data unclear when it comes to the benefits and risks of the drug, which is called Aduhelm. Consequently, only a small minority of these doctors think the medicine should be given to patients with early-onset Alzheimer’s, the patient population that was studied by the drug maker.
Specifically, 87% of the doctors either disagreed or strongly disagreed with the FDA’s decision to approve the drug. Meanwhile, only 47% of the neurologists and just 34% of the primary care doctors believe they have enough information to make a prescribing decision. The poll of 197 physicians was conducted online between June 14 and June 23.
About the Author Reprints
Create a display name to comment
This name will appear with your comment
